FDAnews Drug Daily Bulletin

NASTECH PHARMACEUTICAL COMPANY INC. ANNOUNCES MULTI-COMPOUND AGREEMENT WITH NOVO NORDISK A/S

March 16, 2006
A A

Nastech Pharmaceutical Company Inc., a leader in developing therapeutics using advanced molecular biology-based drug delivery technologies, announced today that it has entered into a multi-compound, feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds. Specific compounds and indications were not announced. Financial and other terms were not disclosed. Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=381059)